Antiviral drugs on influenza are important in the control program of influenza. Options for influenza treatment are currently limited to using the neuraminidase inhibitors (NAIs). Given limited effectiveness of NAIs and related resistance, there remains an urgent need for the development of influenza antiviral drugs that can improve the efficacy and provide low propensity of viral resistance. Several influenza-related antiviral drugs that are currently under the late-stage clinical trials all appear differently in the mechanism of action. It is hoped that when new antiviral drugs are licensed, care and outcomes of severe influenza cases will be improved.
抗流感病毒治疗作为救治流感感染的关键手段，但目前临床可及的有效抗病毒药物仅有神经氨酸酶抑制剂（neuraminidase inhibitors，NAIs）。由于NAIs疗效的限制和耐药情况的出现，亟需研发疗效更优和耐药率更低的新型抗流感病毒药物。目前，诸多不同抗流感病毒机制的药物已处于上市前临床试验阶段。.
Keywords: Antiviral agent; Influenza; Neuraminidase inhibitors; Therapy.